Go back to the newsletter archive

Ash Preview from our Perspective

Dear colleagues,

The 11ᵗʰ International Symposium on Hodgkin Lymphoma (ISHL11) will take place in Cologne, Germany, between October 27 and 29, 2018.

Novel findings in the field of Hodgkin Lymphoma will be presented at the upcoming ASH1 annual meeting held in Atlanta, USA, between December 9 and 12, 2017.


A number of abstracts addressing pre-clinical and clinical aspects on Hodgkin Lymphoma will be presented at this years ASH meeting. The final analysis of the randomized ECHELON-1 study comparing standard ABVD with AVD plus brentuximab vedotin in advanced classical Hodgkin Lymphoma will certainly be one of the highlights and was chosen to be presented at the meetings plenary session.

Link to Abstract

Combination of AVD and brentuximab vedotin

In addition, several interim analyses of early-phase studies evaluating combinations of either targeted drugs and conventional chemotherapy or two targeted drugs will be presented. The combination of AVD and brentuximab vedotin has been investigated in patients with newly diagnosed intermediate-stage classical Hodgkin Lymphoma.

Link to Abstract

Combination of nivolumab and AVD

The combination of the anti-PD-1 antibody nivolumab and AVD was given in patients with previously untreated advanced stage disease.

Link to Abstract

Chemotherapy-free salvage therapy

A chemotherapy-free salvage therapy consisting of brentuximab vedotin and nivolumab was used in patients with Lymphoma recurrence after first-line treatment.

Link to Abstract

Combination of brentuximab vedotin AND ibrutinib

In patients with multiple relapses, initial data from a study combining brentuximab vedotin and the Btk inhibitor ibrutinib will be presented.

Link to Abstract

Several additional abstracts will focus on PET imaging, late effects and the more rare histological subtype of nodular lymphocyte-predominant Hodgkin Lymphoma.

1Please note that ISHL11 is not affiliated with the American Society of Hematology.

Might also be interesting

Early Bird Registration

We are pleased to announce that the online registration for ISHL11 is now open! Early bird registration ends on May 31, 2018.

Register Online

Scientific Program Highlights: Biomarkers

Treatment stratification by PET/CT has improved outcome and reduced treatment toxicity in Hodgkin Lymphoma. Recently, results of the GHSG HD18 trial were presented at EHA 2017. In this study…

Read more…

Developments in Advanced Stages

Latest Results of Large Scale Randomized Phase Ⅲ Trials in Advanced Stage HL

One central question in Hodgkin Lymphoma is the best treatment for advanced stage patients. Initial data of the company-sponsored international ECHELON-1 trial were expected with substantial interest and will be presented at ASH 2017 in detail…

Read more…